Research Paper Volume 15, Issue 13 pp 6302—6330
Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer
Figure 7. The great value of ADAR in the immunotherapy of BLCA. (A) The ADAR high expression group had a higher number of immune cells in the tumor microenvironment. (B) CD4+T cells accounted for a greater proportion of patients with high expression of ADAR. (C, D) ADAR contribute to higher immunotherapy responses. (E) IPS scores on all TCGA-BLCA samples reconfirmed the conclusion that high ADAR expression predicted a better immunotherapy response. (F) The difference boxplot from the immunotherapy cohort IMvigor210 (n = 348). (G) Survival analysis showed that patients in PR and CR groups had significantly better survival expectations than those in PD and SD groups. (H, I) The difference boxplot and survival analysis from the immunotherapy cohort GSE176307 (n = 90).